- Home
- TCMD vs RIGL Comparison
TCMD vs RIGL Comparison
Compare TCMD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | RIGL |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.5M | 564.7M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TCMD | RIGL |
|---|---|---|
| Price | $25.55 | $30.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $36.00 | ★ $45.67 |
| AVG Volume (30 Days) | 342.4K | ★ 405.5K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.14 | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | $12.75 |
| P/E Ratio | ★ N/A | $67.55 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.42 | $18.14 |
| 52 Week High | $37.77 | $52.24 |
Technical Indicators
Market Signals| Indicator | TCMD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 53.97 |
| Support Level | $22.78 | $25.56 |
| Resistance Level | $27.19 | $32.17 |
| Average True Range (ATR) | 0.96 | 1.66 |
| MACD | 0.25 | 0.12 |
| Stochastic Oscillator | 80.90 | 60.19 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.